Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Immediate vs. delayed intervention in non-ST-elevation myocardial infarction

Original Title: Immediate Versus Delayed Invasive Intervention for Non-ST-Segment Elevation Myocardial Infarction Patients The RIDDLE-NSTEMI Study (Randomized study of ImmeDiate versus DeLayedinvasivE intervention in patients with Non-ST-segment Elevation Myocardial Infarction). Reference: J Am CollCardiolIntv. 2016. Online before print.

 

This study assessed the clinical impact of immediate invasive intervention (within 2 hours) vs. delayed intervention (within 2 and 72 hrs.) in non ST myocardial infarction (NSTEMI) patients.

Prior studies have shown contradictory outcomes of the effect of early invasive intervention in heterogeneous populations of NSTEMI patients.

The study randomized 323 NSTEMI patients to immediate intervention (<2 hrs.after randomization, n=162) vs. delayed intervention (2 to 72 hrs.after randomization, n=161).Primary end point was death or new MI at 30 days.

Median time from randomization to angiography was 1.4 hrs. for the immediate intervention group and 61 hrs. for the delayed intervention group.

At 30 days, the primary end point of death and new MI was less frequent in the immediate intervention group (4.3% vs. 13%, HR 0.32, CI 95% 0.13 to 0.74; p= 0.008).

This difference in favor of immediate intervention persisted at one year (6.8% vs. 18.8%, HR 0.34, IC 95% 0.17 a 0.67; p=0.002).

The observed outcomes were mainly explained by a higher rate of new MI in the period between randomization and catheterization in the delayed intervention group (0 deaths and 0 new MIs in the immediate intervention group vs. 1 death and 10 new MIs in the delayed intervention group).

Death, new MI or recurrent ischemia rates were lower in the immediate intervention group, both at 30 days (6.8% vs. 26.7%; p < 0.001) and at 1 year (15.4% vs. 33.1%; p < 0.001).

Conclusion
The immediate invasive strategy in STEMI patients reduces mortality and new MI, compared to a delayed intervention strategy.

Editorial Comment
Prior studies have shown the potential of early interventions in NSTEMI syndromes, however, the advantage has always been based on softer end points such as recurrent ischemia. This work is the first to bring evidence on hard points such as death and MI.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...